ASR Nederland

ASR Nederland NV is a multiline insurance company based in the Netherlands. The Company operates through six segments: Non-Life, comprising non-life insurances, including motor vehicle, fire, travel and leisure, transport, liability, agricultural, construction motorized vehicles and construction all risk and assistance insurance products, among others; Life, offering insurance policies that involve asset-building, asset protection, term life insurance and funeral expenses for consumers and business owners; Banking and Asset Management, providing banking activities and activities related to asset management, including investment property management; Distribution and Services, including the distribution of insurance contracts and intermediary services; Holding and Other, providing primarily holding activities of the Company, as well as Real Estate Development, specialized in the development of real estate properties. The Company operates in the Netherlands and internationally.
  • TickerA2AKBT
  • ISINNL0011872643
  • ExchangeEuronext Amsterdam
  • SectorNonlife Insurance
  • CountryNetherlands

Analysts

ASR NEDERLAND sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of ASR NEDERLAND (NL), a company active in the Full Line Insurance industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date October 11, 2019, the closing price was EUR 34.04 and its potential was estimated at EUR 36.81.

Expert Corporate Governance Service (ECGS)

ASR Nederland - EGM 30 October 2019

In general, ASR Nederland is in compliance with the Dutch regulations relating to the organisation and procedures of the Extraordinary General Meeting.Under ITEM 2a, the supervisory board gives notice of its intention to appoint Ms. Ingrid de Graaf-de Swart as member of the Company's executive board for a period of 4 years. ECGS notes that according to Dutch law and the Company's Articles of Association, shareholders are NOT entitled to vote on this agenda item. Shareholders will have the opportunity though to ask questions or make remarks with respect to this agenda item during the meeting.Un...

Bart Cuypers ...
  • Jason Kalamboussis
  • Sandra Cauwenberghs

Morning Note: ASRNL NA, BOTHE BB, CYAD BB, HEIJM NA, MITRA BB

ASR: Loss of CFO to KPN a blow. Downgrade. Bone Therapeutics: Preclinical ALLOB data at EORS Celyad: mCRC data at SITC Heijmans: Leusden contract of € 30m Mithra: Estelle goes to the US with generic player Mayne

1 director bought

A director at ASR Nederland NV bought 757 shares at 32.390EUR and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Alexander Makar ...
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Thomas Couvreur
  • Wim Hoste

Morning Note: ADYEN NA, ASRNL NA, CYAD BB, TESB BB, VGP BB

Adyen: Founders sell 15% of shares ASR: Genuinely better, and a positive badwill. Upgrade. Celyad: 1H19 – cash lowering, new clinical updates YE19 Tessenderlo: Preview : 1H EBITDA driven by M&A and IFRS16 VGP: 1H19 results: Ongoing strong financial performance

Bart Cuypers ...
  • Jason Kalamboussis
  • Sandra Cauwenberghs

Morning Note: ASRNL NA, BOTHE BB, CYAD BB, HEIJM NA, MITRA BB

ASR: Loss of CFO to KPN a blow. Downgrade. Bone Therapeutics: Preclinical ALLOB data at EORS Celyad: mCRC data at SITC Heijmans: Leusden contract of € 30m Mithra: Estelle goes to the US with generic player Mayne

Alexander Makar ...
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Thomas Couvreur
  • Wim Hoste

Morning Note: ADYEN NA, ASRNL NA, CYAD BB, TESB BB, VGP BB

Adyen: Founders sell 15% of shares ASR: Genuinely better, and a positive badwill. Upgrade. Celyad: 1H19 – cash lowering, new clinical updates YE19 Tessenderlo: Preview : 1H EBITDA driven by M&A and IFRS16 VGP: 1H19 results: Ongoing strong financial performance

Bart Cuypers ...
  • Cedric Duinslaeger
  • Jan Opdecam
  • Jason Kalamboussis
  • Sandra Cauwenberghs
  • Wim Hoste

KBC Securities Morning Note 20-2-2019 AED BB, AGS BB, ASRNL NA, BAMNB NA, CPINV BB, EURN BB, MITRA BB, REC BB, RTL BB, WKL NA

Aedifica: HY18-19: above budget and busy 2H Ageas: Asian miss for 4Q, but Non-Life sharpening its teeth ASR: Good FY results, in line, waiting for VIVAT BAM Group: Solid 4Q18 results CP Invest: Acquisition of € 6.5m in Belgium Euronav: Sold LR1 for $ 6.75m, $ 0.4m gain Mithra: Moving into veterinary applications with CEVA Recticel: Closing of first tranche of Proseat divestment RTL Group: Groupe M6 comfortably beats FY estimates Wolters Kluwer: First look FY18 results

Jan Opdecam ...
  • Jason Kalamboussis
  • Ruben Devos

KBC Securities Morning Note 5-12-2018 ASRNL NA, TNET BB, XIOR BB

ASR: Loyalis, good deal but uncertainty increases Telenet: 3-year outlook and updated capital allocation policy Xior: € 62.6m acquisition in The Netherlands

Bart Cuypers ...
  • Cedric Duinslaeger
  • Jan Opdecam
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Ruben Devos
  • Sandra Cauwenberghs

KBC Securities Morning Note 4-12-2018 ASRNL NA, BCART BB, BPOST BB, CYAD BB, CFEB BB, COFB BB, GBLB BB

ASR: Acquires Loyalis from APG Biocartis: Genomic Health collab expands into urology bpost: Throwing in the towel Celyad: AML: update on CYAD-01 at ASH CFE: SeaMade € 500m EPCI offshore wind contract Cofinimmo: Company note: Investment pipeline shifts up a gear GBL: Passing of Honorary Chairman, Albert Frère

1 director bought

A director at ASR Nederland NV bought 757 shares at 32.390EUR and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

ASR NEDERLAND sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of ASR NEDERLAND (NL), a company active in the Full Line Insurance industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date October 11, 2019, the closing price was EUR 34.04 and its potential was estimated at EUR 36.81.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

ASR Nederland - EGM 30 October 2019

In general, ASR Nederland is in compliance with the Dutch regulations relating to the organisation and procedures of the Extraordinary General Meeting.Under ITEM 2a, the supervisory board gives notice of its intention to appoint Ms. Ingrid de Graaf-de Swart as member of the Company's executive board for a period of 4 years. ECGS notes that according to Dutch law and the Company's Articles of Association, shareholders are NOT entitled to vote on this agenda item. Shareholders will have the opportunity though to ask questions or make remarks with respect to this agenda item during the meeting.Un...

Matthieu DRIOL

Short term view - ASR NEDERLAND NV : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at €43.02. Breaking below the support at €36.28 would invalidate the trend.

Matthieu DRIOL

Analyse court terme - ASR NEDERLAND NV : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 43,02 €. La rupture du support à 36,28 € invaliderait cette tendance.

Matthieu DRIOL

Short term view - ASR NEDERLAND NV : Falling.

The trend is bullish. The current fall looks like a consolidation. The support at €38.48 could cause a bullish reaction towards €43.02. The break of €36.28 would endanger the trend.

Matthieu DRIOL

Analyse court terme - ASR NEDERLAND NV : Baisse en cours.

La tendance est haussière. La baisse en cours s'apparente à une consolidation. Le support à 38,48 € pourrait relancer le mouvement haussier vers 43,02 €. La rupture de 36,28 € mettrait la tendance en danger.

Matthieu DRIOL

Medium term view - ASR NEDERLAND NV : The background trend is clearly bullish.

The background trend is clearly bullish. Prices are still making progress. The following targets are at €42.30 and €48.03. The trend would be invalidated below the support at €29.34.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch